Nutex Health, Inc.
NASDAQ:NUTXMedical - Healthcare Information Services
+$2.84 today
- Market cap
- $1.19B
- Beta
- 2.06
- P/E (TTM)
- 10.4
- EPS (TTM)
- $14.38
Volume 0.16M
Average 0.17M
NUTX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Nutex Health, Inc.NASDAQ: NUTX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA grows, but more slowly than its trailing trend
Q1 FY2026 EBITDA of $86.73M rose 17.2% year over year, behind the +36.3% change in trailing-twelve-month EBITDA. Sequentially, it rose 140.2% from the prior quarter.
Context
- EBITDA amounted to 32.9% of revenue in FY2025, up 1.9 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $310.34M (+7.9%) for the fiscal year ending Dec 2026, a slowdown from the +93.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $86.73M+140.2% QoQ
- Last fiscal yearDec 2025
- $287.54M+93.4% YoY
- LTMMar 2026
- $291.89M+36.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +17.2% | +73.0% | +55.7 pp |
| 1 year | +93.4% | +7.9% | -85.5 pp |
| 3-year CAGR | — | +3.4% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 287.54M USD
- Year-over-year change
- +93.4%
- 4-year CAGR
- +11.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 287.54M | +93.4% |
| FY2024 | 2024-12-31 | 148.65M | +1119.5% |
| FY2023 | 2023-12-31 | (14.58M) | +96.3% |
| FY2022 | 2022-12-31 | (394.03M) | -314.8% |
| FY2021 | 2021-12-31 | 183.45M | — |
EBITDA vs competitors
How NUTX compares with its peers on the latest reported figures
- NUTX's LTM Mar 2026 EBITDA of $291.89M is the 8th highest of the 11 companies compared; the peer median is $586.58M.
- Its year-over-year change of +36.3% is the 3rd highest of 11, against a peer median of +15.5%.
- EBITDA amounts to 33.2% of revenue for NUTX, versus a peer median of 17.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.06B | +9.6% | +13.4% | 23.2% | |
| LTM Mar 2026 | $4.96B | +296.6% | +20.0% | 23.1% | |
| LTM Jun 2026 | $2.82B | +16.2% | +20.3% | 15.6% | |
| LTM Jun 2026 | $1.5B | +14.8% | +17.3% | 24.2% | |
| LTM Sep 2026 | $667.4M | -18.3% | +7.1% | 19.9% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $505.76M | -10.5% | -2.2% | 7.9% |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $478.53M | +19.3% | +7.4% | 20.5% |
| LTM Mar 2026 | $291.89M | +36.3% | — | 33.2% | |
| LTM Mar 2026 | $162.81M | +26.3% | +6.5% | 4.6% | |
| LTM Mar 2026 | $4.36M | +191.5% | -28.5% | 0.5% | |
| LTM Mar 2026 | -$340.64M | -53.6% | — | 5.9% | |
| Peer median (excluding NUTX) | $586.58M | +15.5% | +7.4% | 17.7% | |
Competitors are the stored peer set for NUTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 331.53M | 219.29M | 247.65M | 479.95M | 875.26M |
| Cost of Revenue | 152.25M | 203.87M | 212.87M | 283.69M | 430.98M |
| Gross Profit | 179.28M | 15.42M | 34.77M | 196.26M | 444.28M |
| Gross Margin | 54.1% | 7.0% | 14.0% | 40.9% | 50.8% |
| Research & Development | 285.88K | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 5.46M | 20M | 36.07M | 58.56M | 168.66M |
| Operating Expenses | 9.02M | 422.02M | 66.55M | 65.64M | 168.66M |
| Depreciation & Amortization | 7.76M | 13.13M | 17.59M | 18.97M | 20.53M |
| EBITDA | 183.45M | (394.03M) | (14.58M) | 148.65M | 287.54M |
| EBITDA Margin | 55.3% | -179.7% | -5.9% | 31.0% | 32.9% |
| Operating Income | 170.26M | (406.6M) | (31.77M) | 130.62M | 275.63M |
| Operating Margin | 51.4% | -185.4% | -12.8% | 27.2% | 31.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 6.2M | 12.49M | 16.32M | 19.93M | 22.23M |
| Other Income / Expenses | (773.88K) | (13.05M) | (16.72M) | (20.87M) | (30.84M) |
| Income Before Tax | 169.49M | (419.65M) | (48.49M) | 109.75M | 244.78M |
| Pre-Tax Margin | 51.1% | -191.4% | -19.6% | 22.9% | 28.0% |
| Income Tax Expense | 965.73K | 13.09M | (5.07M) | 14.48M | 64.42M |
| Net Income | 132.59M | (424.78M) | (45.79M) | 52.18M | 70.79M |
| Net Margin | 40.0% | -193.7% | -18.5% | 10.9% | 8.1% |
| EPS (Basic) | 33.55 | (100.50) | (10.39) | 10.23 | 11.13 |
| EPS (Diluted) | 33.55 | (100.36) | (10.39) | 9.71 | 10.48 |
| Weighted Avg Shares | 4.02M | 4.23M | 4.41M | 5.1M | 6.36M |
| Weighted Avg Shares (Diluted) | 3.95M | 4.23M | 4.41M | 5.1M | 6.76M |
Nutex Health, Inc.
NASDAQ:NUTX
Intrinsic Alpha fair value
Locked
Current Price
$172.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.